About: DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Sector: Healthcare
Industry: Biotechnology
Latest price: $9.15 (-4.24%)
DBVT NASDAQ DBV Technologies
DBV Technologies share price
DBVT price activity
Last Price
$9.150
Change (24hr)
-0.41 USD (-4.24%)
Volume
182.19K
Volume (4w avg)
-
Open
$9.46
Day Range
$9.15 - $9.46
Previous Close
$9.55
Last Trade
13 Oct, 3:49 pm GMT+0
Delayed
13 Oct, 3:49 pm GMT+0
DBVT price performance
Delayed
13 Oct, 3:49 pm GMT+0
DBVT Market Signals